Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
    • The Flipside
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech
An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
    • The Flipside
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech

Understanding Potentially Preventable 7-Day Readmission Rates in Medical Oncology Patients

Clinical question: What are the rates and the underlying risk factors for seven-day, unplanned, potentially preventable re-admission (PPR), among solid tumor patients in a medical oncology ward?

Background: The rate of unplanned 30-day readmissions at tertiary cancer centers has been estimated to be 22%, with a median time to readmission of nine to 10 days. Some studies have found that the frequency of PPRs is higher within seven days of discharge compared to those occurring between eight and 30 days post-discharge.

Study design: Retrospective cohort study

Setting: MD Anderson Cancer Center, Houston, Texas

Synopsis: The hospital medicine department at MD Anderson Cancer Center admits adult patients with solid tumors. This study was performed from September 1, 2020, to February 28, 2021. Readmissions were independently analyzed by two randomly assigned providers. Of 138 unplanned readmissions within seven days, 22 (15.9%) were deemed preventable. The median age was 62.5 years and 52.9% were female. The most common cancer type was non-colon GI, liver, or pancreatic cancer (34.06%), followed by colorectal and lung cancer. Most patients had stage 4 cancer (69.6%) and were discharged to home (64.9%).

The most commonly cited reasons for potential preventability were possible premature discharge, followed by missed opportunities for goals-of-care discussion, lack of one-week outpatient follow-up, and discharge medication errors. Reviewers attributed possible premature discharges to incomplete evaluation and management of medical problems and uncontrolled symptoms such as pain or recurrent ascites. Decreasing the 30-day readmission rate in cancer patients may be challenging due to new or worsening symptoms related to cancer progression or treatment. There may be more opportunities to prevent seven-day unplanned readmissions.

Bottom line: Premature discharge followed by missed opportunity for goals-of-care discussions were the most common reasons for potentially preventable seven-day readmissions.

Citation: Leung CK, et al. Understanding potentially preventable 7-day readmission rates in hospital medicine patients at a comprehensive cancer center. American College of Medical Quality 2024; 39(1):14-20.

Dr. Prystupa

Dr. Prystupa is a hospitalist in the division of hospital medicine at the Mount Sinai Health System and an assistant professor of medicine at the Icahn School of Medicine at Mount Sinai in New York. n

  • Understanding Potentially Preventable 7-Day Readmission Rates in Medical Oncology Patients

    January 1, 2025

  • SHM Hill Day 2024

    January 1, 2025

  • Global Hospital Medicine

    January 1, 2025

  • Illicit Medetomidine Use with Fentanyl

    January 1, 2025

  • Running Dry: How Hospitalists Can Conquer the IV Fluid Crisis

    January 1, 2025

  • Residents Look Forward to a New Year

    January 1, 2025

  • Job Hunt Essentials for Hospitalists

    January 1, 2025

  • Coding Corner: Come on In (Patient)!

    December 2, 2024

  • Hospital Medicine Now and in the Future: Ad Astra Per Aspera

    December 2, 2024

  • Higher Rates of Major Hemorrhage with Rivaroxaban and Warfarin

    December 2, 2024

1 … 18 19 20 21 22 … 973
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies.
    ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • SHM’s DE&I Statement
  • Cookie Preferences